Logo image of LMNX

Luminex Corp (LMNX) Stock Fundamental Analysis

NASDAQ:LMNX - Nasdaq -

36.99  +0.01 (+0.03%)

After market: 37 +0.01 (+0.03%)

Fundamental Rating

3

Overall LMNX gets a fundamental rating of 3 out of 10. We evaluated LMNX against 55 industry peers in the Life Sciences Tools & Services industry. LMNX may be in some trouble as it scores bad on both profitability and health. LMNX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LMNX had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 2.88%
ROE 4.84%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 12.4%
PM (TTM) 5.39%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

LMNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 4.59 indicates that LMNX is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.52 indicates that LMNX is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z 4.59
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

LMNX has a Current Ratio of 8.37. This indicates that LMNX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 6.08 indicates that LMNX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 6.08

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 563.64% over the past year.
Measured over the past years, LMNX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -18.61% on average per year.
The Revenue has grown by 27.73% in the past year. This is a very strong growth!
The Revenue has been growing by 11.92% on average over the past years. This is quite good.
EPS 1Y (TTM)563.64%
EPS 3Y-18.22%
EPS 5Y-18.61%
EPS Q2Q%533.33%
Revenue 1Y (TTM)27.73%
Revenue growth 3Y10.83%
Revenue growth 5Y11.92%
Sales Q2Q%22.41%

3.2 Future

Based on estimates for the next years, LMNX will show a very strong growth in Earnings Per Share. The EPS will grow by 50.43% on average per year.
LMNX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.14% yearly.
EPS Next Y159.95%
EPS Next 2Y78.43%
EPS Next 3Y72.36%
EPS Next 5Y50.43%
Revenue Next Year16.71%
Revenue Next 2Y12.52%
Revenue Next 3Y11.99%
Revenue Next 5Y12.14%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LMNX Yearly Revenue VS EstimatesLMNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
LMNX Yearly EPS VS EstimatesLMNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LMNX is valuated quite expensively with a Price/Earnings ratio of 72.53.
When comparing the Price/Earnings ratio of LMNX to the average of the S&P500 Index (24.95), we can say LMNX is valued expensively.
Based on the Price/Forward Earnings ratio of 33.19, the valuation of LMNX can be described as expensive.
LMNX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.99.
Industry RankSector Rank
PE 72.53
Fwd PE 33.19
LMNX Price Earnings VS Forward Price EarningsLMNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.82
LMNX Per share dataLMNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LMNX's earnings are expected to grow with 72.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y78.43%
EPS Next 3Y72.36%

More info and screens

3

5. Dividend

5.1 Amount

LMNX has a Yearly Dividend Yield of 1.08%. Purely for dividend investing, there may be better candidates out there.
Compared to an average S&P500 Dividend Yield of 2.41, LMNX's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.08%

5.2 History

On average, the dividend of LMNX grows each year by 13.62%, which is quite nice.
LMNX has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)13.62%
Div Incr YearsN/A
Div Non Decr YearsN/A
LMNX Yearly Dividends per shareLMNX Yearly Dividends per shareYearly Dividends per share 2017 2018 2019 2020 2021 0.1 0.2 0.3

5.3 Sustainability

72.38% of the earnings are spent on dividend by LMNX. This is not a sustainable payout ratio.
The dividend of LMNX is growing, but earnings are growing more, so the dividend growth is sustainable.
DP72.38%
EPS Next 2Y78.43%
EPS Next 3Y72.36%
LMNX Dividend Payout.LMNX Dividend Payout, showing the Payout Ratio.LMNX Dividend Payout.PayoutRetained Earnings

More info and screens

Luminex Corp

NASDAQ:LMNX (7/13/2021, 8:00:00 PM)

After market: 37 +0.01 (+0.03%)

36.99

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners4.04%
Ins Owner Change0%
Market Cap1.75B
Analysts60
Price Target37.74 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.08%
Yearly Dividend0.4
Dividend Growth(5Y)13.62%
DP72.38%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 72.53
Fwd PE 33.19
P/S 4
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB N/A
EV/EBITDA 18.82
EPS(TTM)0.51
EY1.38%
EPS(NY)1.11
Fwd EY3.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS9.25
BVpS10.32
TBVpSN/A
PEG (NY)0.45
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.88%
ROE 4.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 12.4%
PM (TTM) 5.39%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.37
Quick Ratio 6.08
Altman-Z 4.59
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)563.64%
EPS 3Y-18.22%
EPS 5Y-18.61%
EPS Q2Q%533.33%
EPS Next Y159.95%
EPS Next 2Y78.43%
EPS Next 3Y72.36%
EPS Next 5Y50.43%
Revenue 1Y (TTM)27.73%
Revenue growth 3Y10.83%
Revenue growth 5Y11.92%
Sales Q2Q%22.41%
Revenue Next Year16.71%
Revenue Next 2Y12.52%
Revenue Next 3Y11.99%
Revenue Next 5Y12.14%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A